BRIDGEWATER, N.J., Nov. 5, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the Lazard Capital Markets 7th Annual Healthcare Conference in New York. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Tuesday, November 16, 2010, at 4:10 p.m. Eastern Time, at the St. Regis Hotel, 2 East 55th Street, New York, NY 10022.
A live webcast of the presentation will be available, and can be accessed for 90 days following the conference, by visiting .
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC). Founded in 2005, Aegerion is headquartered in Bridgewater, NJ.
CONTACT: Aegerion Pharmaceuticals, Inc. Will Lewis, President +1 (908) 704-1300 LaVoie Group, Inc. Investors & Media Liz Pingpank +1 (978) 745-4200 x104 lpingpank@lavoiegroup.com